GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance ...
The total number of Hyperfine AI-powered marketing authorizations places the company in a leading position on recently published FDA list. GUILFORD, Conn.--(BUSINESS WIRE)-- Hyperfine (Nasdaq: HYPR), ...
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® ...
President and CEO Maria Sainz reported first quarter revenue of $2.1 million from six system sales, noting this quarter marks the end of a period where the business relied mainly on U.S. hospital ...
Hosted on MSN
Hyperfine targets 10–20% revenue growth for 2025 following FDA clearances and next-gen Swoop system launch
CEO Maria Sainz stated that "in the second quarter of 2025, we delivered revenue of $2.7 million up 26% sequentially with the sale of 8 systems, including the sale of our first next-generation Swoop ...
The MarketWatch News Department was not involved in the creation of this content. Hyperfine Delivers Quarterly Record Revenue of Approximately $5.3 Million in Q4 2025, Representing Transformative ...
Rafael O’Halloran, PhD, and Rob Fasciano, PhD, bring depth and breadth of experience in imaging and Medtech. Rob Fasciano, PhD, joined Hyperfine as Chief Regulatory and Quality Officer, bringing over ...
For the first half of 2025, management now expects revenue in the range of $5 million to $6 million, citing recent U.S. deal losses due to grant funding cancellations at academic institutions. For the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results